Other languages Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
3.47 ^USD	-4.14%		0.00%	-21.14%

09/04	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
04/04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09/04
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Top Premarket Decliners	13/23/13
Top Premarket Decliners	12/23/12
Tempest Therapeutics' TPST-1120 Combination Therapy Delivers Improved Results in Updated Liver Cancer Study; Shares Jump	11/23/11
Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study	11/23/11
Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development	19/23/19
Tempest Therapeutics, Inc. Announces Executive Changes	08/23/08
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers	26/23/26
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Top Midday Gainers	28/23/28
Tempest Therapeutics, Inc. Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma	28/23/28
Tempest Therapeutics, Inc. Announces New Data from its TPST-1120 and TREX1 Programs at 2023 AACR Annual Meeting	17/23/17
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23
Tempest Therapeutics, Inc. to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Other languages

Filters